Search

Your search keyword '"Mucci, Lorelei A."' showing total 2,171 results
Start Over Author "Mucci, Lorelei A."
2,171 results on '"Mucci, Lorelei A."'

152. Table S1, S2, S3 from Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate

Author

Elfandy, Habiba, primary, Armenia, Joshua, primary, Pederzoli, Filippo, primary, Pullman, Eli, primary, Pertega-Gomes, Nelma, primary, Schultz, Nikolaus, primary, Viswanathan, Kartik, primary, Vosoughi, Aram, primary, Blattner, Mirjam, primary, Stopsack, Konrad H., primary, Zadra, Giorgia, primary, Penney, Kathryn L., primary, Mosquera, Juan Miguel, primary, Tyekucheva, Svitlana, primary, Mucci, Lorelei A., primary, Barbieri, Christopher, primary, and Loda, Massimo, primary

Published
2023
Full Text
View/download PDF

155. Perspective on this Article from A Large Prospective Study of SEP15 Genetic Variation, Interaction with Plasma Selenium Levels, and Prostate Cancer Risk and Survival

Author

Penney, Kathryn L., primary, Schumacher, Fredrick R., primary, Li, Haojie, primary, Kraft, Peter, primary, Morris, J. Steven, primary, Kurth, Tobias, primary, Mucci, Lorelei A., primary, Hunter, David J., primary, Kantoff, Philip W., primary, Stampfer, Meir J., primary, and Ma, Jing, primary

Published
2023
Full Text
View/download PDF

157. Supplementary Tables 1-5, Supplementary Figures 1-3 from Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions

Author

Stopsack, Konrad H., primary, Su, Xiaofeng A., primary, Vaselkiv, J. Bailey, primary, Graff, Rebecca E., primary, Ebot, Ericka M., primary, Pettersson, Andreas, primary, Lis, Rosina T., primary, Fiorentino, Michelangelo, primary, Loda, Massimo, primary, Penney, Kathryn L., primary, Lotan, Tamara L., primary, and Mucci, Lorelei A., primary

Published
2023
Full Text
View/download PDF

158. Data from Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate

Author

Elfandy, Habiba, primary, Armenia, Joshua, primary, Pederzoli, Filippo, primary, Pullman, Eli, primary, Pertega-Gomes, Nelma, primary, Schultz, Nikolaus, primary, Viswanathan, Kartik, primary, Vosoughi, Aram, primary, Blattner, Mirjam, primary, Stopsack, Konrad H., primary, Zadra, Giorgia, primary, Penney, Kathryn L., primary, Mosquera, Juan Miguel, primary, Tyekucheva, Svitlana, primary, Mucci, Lorelei A., primary, Barbieri, Christopher, primary, and Loda, Massimo, primary

Published
2023
Full Text
View/download PDF

159. Supplemental Table 1 and 2 from Prediagnostic Obesity and Physical Inactivity Are Associated with Shorter Telomere Length in Prostate Stromal Cells

Author

Joshu, Corinne E., primary, Peskoe, Sarah B., primary, Heaphy, Christopher M., primary, Kenfield, Stacey A., primary, Van Blarigan, Erin L., primary, Mucci, Lorelei A., primary, Giovannucci, Edward L., primary, Stampfer, Meir J., primary, Yoon, GhilSuk, primary, Lee, Thomas K., primary, Hicks, Jessica L., primary, De Marzo, Angelo M., primary, Meeker, Alan K., primary, and Platz, Elizabeth A., primary

Published
2023
Full Text
View/download PDF

161. Table S9, S10 from Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate

Author

Elfandy, Habiba, primary, Armenia, Joshua, primary, Pederzoli, Filippo, primary, Pullman, Eli, primary, Pertega-Gomes, Nelma, primary, Schultz, Nikolaus, primary, Viswanathan, Kartik, primary, Vosoughi, Aram, primary, Blattner, Mirjam, primary, Stopsack, Konrad H., primary, Zadra, Giorgia, primary, Penney, Kathryn L., primary, Mosquera, Juan Miguel, primary, Tyekucheva, Svitlana, primary, Mucci, Lorelei A., primary, Barbieri, Christopher, primary, and Loda, Massimo, primary

Published
2023
Full Text
View/download PDF

162. Table S11 from Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate

Author

Elfandy, Habiba, primary, Armenia, Joshua, primary, Pederzoli, Filippo, primary, Pullman, Eli, primary, Pertega-Gomes, Nelma, primary, Schultz, Nikolaus, primary, Viswanathan, Kartik, primary, Vosoughi, Aram, primary, Blattner, Mirjam, primary, Stopsack, Konrad H., primary, Zadra, Giorgia, primary, Penney, Kathryn L., primary, Mosquera, Juan Miguel, primary, Tyekucheva, Svitlana, primary, Mucci, Lorelei A., primary, Barbieri, Christopher, primary, and Loda, Massimo, primary

Published
2023
Full Text
View/download PDF

163. Supplementary Figures S1-S6 from Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate

Author

Elfandy, Habiba, primary, Armenia, Joshua, primary, Pederzoli, Filippo, primary, Pullman, Eli, primary, Pertega-Gomes, Nelma, primary, Schultz, Nikolaus, primary, Viswanathan, Kartik, primary, Vosoughi, Aram, primary, Blattner, Mirjam, primary, Stopsack, Konrad H., primary, Zadra, Giorgia, primary, Penney, Kathryn L., primary, Mosquera, Juan Miguel, primary, Tyekucheva, Svitlana, primary, Mucci, Lorelei A., primary, Barbieri, Christopher, primary, and Loda, Massimo, primary

Published
2023
Full Text
View/download PDF

165. Supplementary Tables S1 - S5, Figures S1 - S5 from A Large Multiethnic Genome-Wide Association Study of Prostate Cancer Identifies Novel Risk Variants and Substantial Ethnic Differences

Author

Hoffmann, Thomas J., primary, Van Den Eeden, Stephen K., primary, Sakoda, Lori C., primary, Jorgenson, Eric, primary, Habel, Laurel A., primary, Graff, Rebecca E., primary, Passarelli, Michael N., primary, Cario, Clinton L., primary, Emami, Nima C., primary, Chao, Chun R., primary, Ghai, Nirupa R., primary, Shan, Jun, primary, Ranatunga, Dilrini K., primary, Quesenberry, Charles P., primary, Aaronson, David, primary, Presti, Joseph, primary, Wang, Zhaoming, primary, Berndt, Sonja I., primary, Chanock, Stephen J., primary, McDonnell, Shannon K., primary, French, Amy J., primary, Schaid, Daniel J., primary, Thibodeau, Stephen N., primary, Li, Qiyuan, primary, Freedman, Matthew L., primary, Penney, Kathryn L., primary, Mucci, Lorelei A., primary, Haiman, Christopher A., primary, Henderson, Brian E., primary, Seminara, Daniela, primary, Kvale, Mark N., primary, Kwok, Pui-Yan, primary, Schaefer, Catherine, primary, Risch, Neil, primary, and Witte, John S., primary

Published
2023
Full Text
View/download PDF

168. Supplementary Data from Family History of Prostate and Breast Cancer Integrated with a Polygenic Risk Score Identifies Men at Highest Risk of Dying from Prostate Cancer before Age 75 Years

Author

Plym, Anna, primary, Zhang, Yiwen, primary, Stopsack, Konrad H., primary, Jee, Yon Ho, primary, Wiklund, Fredrik, primary, Kibel, Adam S., primary, Kraft, Peter, primary, Giovannucci, Edward, primary, Penney, Kathryn L., primary, and Mucci, Lorelei A., primary

Published
2023
Full Text
View/download PDF

169. A Healthy Lifestyle in Men at Increased Genetic Risk for Prostate Cancer

Author

Plym, Anna, primary, Zhang, Yiwen, additional, Stopsack, Konrad H., additional, Delcoigne, Bénédicte, additional, Wiklund, Fredrik, additional, Haiman, Christopher, additional, Kenfield, Stacey A., additional, Kibel, Adam S., additional, Giovannucci, Edward, additional, Penney, Kathryn L., additional, and Mucci, Lorelei A., additional

Published
2023
Full Text
View/download PDF

170. Addition of a Genetic Risk Score for Identification of Men with a Low Prostate-specific Antigen Level in Midlife at Risk of Developing Lethal Prostate Cancer

Author

Ma, Chaoran, primary, Ericsson, Caroline, additional, Carlsson, Sigrid V., additional, Lilja, Hans, additional, Kibel, Adam, additional, Graff, Rebecca E., additional, Plym, Anna, additional, Giovannucci, Edward, additional, Mucci, Lorelei A., additional, Preston, Mark A., additional, and Penney, Kathryn L., additional

Published
2023
Full Text
View/download PDF

173. Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry

Author

Matejcic, Marco, Saunders, Edward J., Dadaev, Tokhir, Brook, Mark N., Wang, Kan, Sheng, Xin, Olama, Ali Amin Al, Schumacher, Fredrick R., Ingles, Sue A., Govindasami, Koveela, Benlloch, Sara, Berndt, Sonja I., Albanes, Demetrius, Koutros, Stella, Muir, Kenneth, Stevens, Victoria L., Gapstur, Susan M., Tangen, Catherine M., Batra, Jyotsna, Clements, Judith, Gronberg, Henrik, Pashayan, Nora, Schleutker, Johanna, Wolk, Alicja, West, Catharine, Mucci, Lorelei, Kraft, Peter, Cancel-Tassin, Géraldine, Sorensen, Karina D., Maehle, Lovise, Grindedal, Eli M., Strom, Sara S., Neal, David E., Hamdy, Freddie C., Donovan, Jenny L., Travis, Ruth C., Hamilton, Robert J., Rosenstein, Barry, Lu, Yong-Jie, Giles, Graham G., Kibel, Adam S., Vega, Ana, Bensen, Jeanette T., Kogevinas, Manolis, Penney, Kathryn L., Park, Jong Y., Stanford, Janet L., Cybulski, Cezary, Nordestgaard, Børge G., Brenner, Hermann, Maier, Christiane, Kim, Jeri, Teixeira, Manuel R., Neuhausen, Susan L., De Ruyck, Kim, Razack, Azad, Newcomb, Lisa F., Lessel, Davor, Kaneva, Radka, Usmani, Nawaid, Claessens, Frank, Townsend, Paul A., Gago-Dominguez, Manuela, Roobol, Monique J., Menegaux, Florence, Khaw, Kay-Tee, Cannon-Albright, Lisa A., Pandha, Hardev, Thibodeau, Stephen N., Schaid, Daniel J., The PRACTICAL Consortium, Wiklund, Fredrik, Chanock, Stephen J., Easton, Douglas F., Eeles, Rosalind A., Kote-Jarai, Zsofia, Conti, David V., and Haiman, Christopher A.

Published
2019
Full Text
View/download PDF

174. Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy.

Author

Feng, Xiaoshuang, Zhang, Yiwen, Vaselkiv, J. Bailey, Li, Ruifeng, Nguyen, Paul L., Penney, Kathryn L., Giovannucci, Edward L., Mucci, Lorelei A., and Stopsack, Konrad H.

Abstract

Background: Previously suggested modifiable risk factors for prostate cancer could have resulted from detection bias because diagnosis requires a biopsy. We investigated modifiable risk factors for a subsequent cancer diagnosis among men with an initially negative prostate biopsy. Methods: In total, 10,396 participants of the Health Professionals Follow-up Study with an initial negative prostate biopsy after 1994 were followed for incident prostate cancer until 2017. Potential risk factors were based on previous studies in the general population. Outcomes included localised, advanced, and lethal prostate cancer. Results: With 1851 prostate cancer cases (168 lethal) diagnosed over 23 years of follow-up, the 20-year risk of any prostate cancer diagnosis was 18.5% (95% CI: 17.7–19.3). Higher BMI and lower alcohol intake tended to be associated with lower rates of localised disease. Coffee, lycopene intake and statin use tended to be associated with lower rates of lethal prostate cancer. Results for other risk factors were less precise but compatible with and of similar direction as for men in the overall cohort. Conclusions: Risk factors for future prostate cancer among men with a negative biopsy were generally consistent with those for the general population, supporting their validity given reduced detection bias, and could be actionable, if confirmed. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

175. Germline Genetic Variants Associated with Somatic TMPRSS2:ERG Fusion Status in Prostate Cancer: A Genome-Wide Association Study.

Author

Chaoran Ma, Xiaoyu Wang, Dai, James Y., Turman, Constance, Kraft, Peter, Stopsack, Konrad H., Loda, Massimo, Pettersson, Andreas, Mucci, Lorelei A., Stanford, Janet L., and Penney, Kathryn L.

Abstract

Background: The prostate cancer subtype defined by the presence of TMPRSS2:ERG has been shown to be molecularly and epidemiologically distinct. However, few studies have investigated germline genetic variants associating with TMPRSS2:ERG fusion status. Methods: We performed a genome-wide association study with 396 TMPRSS2:ERG(+) cases, 390 TMPRSS2:ERG(-) cases, and 2,386 cancer-free controls from the Physicians' Health Study (PHS), the Health Professionals Follow-up Study (HPFS), and a Seattle-based Fred Hutchinson (FH) Cancer Center Prostate Cancer Study. We applied logistic regression models to test the associations between ~5 million SNPs with TMPRSS2:ERG fusion status accounting for population stratification. Results: We did not identify genome-wide significant variants comparing the TMPRSS2:ERG(+) to the TMPRSS2:ERG(-) prostate cancer cases in the meta-analysis. When comparing TMPRSS2:ERG(+) prostate cancer cases with controls without prostate cancer, 10 genome-wide significant SNPs on chromosome 17q24.3 were observed in the meta-analysis. When comparing TMPRSS2:ERG(-) prostate cancer cases with controls without prostate cancer, two SNPs on chromosome 8q24.21 in the meta-analysis reached genome-wide significance. Conclusions: We observed SNPs at several known prostate cancer risk loci (17q24.3, 1q32.1, and 8q24.21) that were differentially and exclusively associated with the risk of developing prostate tumors either with or without the gene fusion. Impact: Our findings suggest that tumors with the TMPRSS2:ERG fusion exhibit a different germline genetic etiology compared with fusion negative cases. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

176. Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial.

Author

Yim, Kendrick, Ma, Chaoran, Carlsson, Sigrid, Lilja, Hans, Mucci, Lorelei, Penney, Kathryn, Kibel, Adam S., Eggener, Scott, and Preston, Mark A.

Subjects
PROSTATE cancer, PROSTATE-specific antigen, EARLY detection of cancer, PROSTATE cancer patients, OLDER men, FAMILY history (Medicine)
Abstract

Purpose: We studied whether adding percent free PSA to total PSA improves prediction of clinically significant prostate cancer and fatal prostate cancer. Materials and Methods: A total of 6,727 men within the intervention arm of PLCO (Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial) had baseline percent free PSA. Of this cohort, 475 had clinically significant prostate cancer and 98 had fatal prostate cancer. Cumulative incidence and Cox analyses were conducted to evaluate the association between percent free PSA/PSA and clinically significant prostate cancer/fatal prostate cancer. Harrell’s C index evaluated predictive ability. Kaplan-Meier analysis assessed survival. Results: Median follow-up was 19.7 years, median baseline PSA was 1.19 ng/mL, median percent free PSA was 18%. Cumulative incidence of fatal prostate cancer for men with baseline PSA ≥2 ng/mL and percent free PSA ≤10 was 3.2% and 6.1% at 15 and 25 years, respectively, compared to 0.03% and 1.1% for men with percent free PSA >25%. In younger men (55-64 years) with baseline PSA 2-10 ng/mL, C index improved from 0.56 to 0.60 for clinically significant prostate cancer and from 0.53 to 0.64 for fatal prostate cancer with addition of percent free PSA. In older men (65-74 years), C index improved for clinically significant prostate cancer from 0.60 to 0.66, with no improvement in fatal prostate cancer. Adjusting for age, digital rectal exam, family history of prostate cancer, and total PSA, percent free PSA was associated with clinically significant prostate cancer (HR 1.05, P < .001) per 1% decrease. Percent free PSA improved prediction of clinically significant prostate cancer and fatal prostate cancer for all race groups. Conclusions: In a large U.S. screening trial, the addition of percent free PSA to total PSA in men with baseline PSA ≥2 ng/mL improved prediction of clinically significant prostate cancer and fatal prostate cancer. Free PSA should be used to risk-stratify screening and decrease unnecessary prostate biopsies. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

177. Different operationalizations of the 2018 WCRF/AICR cancer prevention recommendations and risk of cancer.

Author

Song, Rui, Riseberg, Emily, Petimar, Joshua, Wang, Molin, Mucci, Lorelei A., Wu, Kana, Zhang, Xuehong, Willett, Walter C., Giovannucci, Edward L., and Smith-Warner, Stephanie A.

Abstract

Background: The standardized scoring system assessing adherence to the 2018 World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) cancer prevention recommendations assigns equal weight for each recommendation, thereby giving higher weight to dietary factors collectively (5 points) than adiposity (1 point) and physical activity (1 point). An alternative score assigning equal weights to the adiposity, physical activity, alcohol, and other dietary (composite) recommendations may better predict cancer associations. Methods: We examined associations between standardized and alternative scores with cancer risk in two US prospective cohorts. Multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox regression. Results: During 28 years of follow-up, 16,342 incident cancer cases in women and 8729 cases in men occurred. Individuals in the highest versus lowest quintile of the standardized score had a reduced overall cancer risk (women: HR = 0.89, 95% CI: 0.85, 0.94; men: HR = 0.87, 95% CI: 0.81, 0.94). Results were slightly stronger for the alternative score (women: HR = 0.83, 95% CI: 0.79, 0.87; men: HR = 0.81, 95% CI: 0.75, 0.86). Similar patterns were observed for obesity-related, alcohol-related, smoking-related, and digestive system cancers. Conclusions: Greater adherence to the WCRF/AICR cancer prevention recommendations was associated with lower cancer risk. A score assigning equal weights to the adiposity, physical activity, alcohol, and all remaining diet components yielded stronger associations than the standardized score. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

180. Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry

Author

Darst, Burcu F., Shen, Jiayi, Madduri, Ravi K., Rodriguez, Alexis A., Xiao, Yukai, Sheng, Xin, Saunders, Edward J., Dadaev, Tokhir, Brook, Mark N., Hoffmann, Thomas J., Muir, Kenneth, Wan, Peggy, Marchand, Loic Le, Wilkens, Lynne, Wang, Ying, Schleutker, Johanna, MacInnis, Robert J., Cybulski, Cezary, Neal, David E., G. Nordestgaard, Børge, Nielsen, Sune F., Batra, Jyotsna, Clements, Judith A., Grönberg, Henrik, Pashayan, Nora, Travis, Ruth C., Park, Jong Y., Albanes, Demetrius, Weinstein, Stephanie, Mucci, Lorelei A., Hunter, David J., Penney, Kathryn L., Tangen, Catherine M., Hamilton, Robert J., Parent, Marie-Élise, Stanford, Janet L., Koutros, Stella, Wolk, Alicja, Sørensen, Karina D., Blot, William J., Yeboah, Edward D., Mensah, James E., Lu, Yong-Jie, Schaid, Daniel J., Thibodeau, Stephen N., West, Catharine M., Maier, Christiane, Kibel, Adam S., Cancel-Tassin, Géraldine, Menegaux, Florence, John, Esther M., Grindedal, Eli Marie, Khaw, Kay-Tee, Ingles, Sue A., Vega, Ana, Rosenstein, Barry S., Teixeira, Manuel R., Kogevinas, Manolis, Cannon-Albright, Lisa, Huff, Chad, Multigner, Luc, Kaneva, Radka, Leach, Robin J., Brenner, Hermann, Hsing, Ann W., Kittles, Rick A., Murphy, Adam B., Logothetis, Christopher J., Neuhausen, Susan L., Isaacs, William B., Nemesure, Barbara, Hennis, Anselm J., Carpten, John, Pandha, Hardev, De Ruyck, Kim, Xu, Jianfeng, Razack, Azad, Teo, Soo-Hwang, Newcomb, Lisa F., Fowke, Jay H., Neslund-Dudas, Christine, Rybicki, Benjamin A., Gamulin, Marija, Usmani, Nawaid, Claessens, Frank, Gago-Dominguez, Manuela, Castelao, Jose Esteban, Townsend, Paul A., Crawford, Dana C., Petrovics, Gyorgy, Casey, Graham, Roobol, Monique J., Hu, Jennifer F., Berndt, Sonja I., Van Den Eeden, Stephen K., Easton, Douglas F., Chanock, Stephen J., Cook, Michael B., Wiklund, Fredrik, Witte, John S., Eeles, Rosalind A., Kote-Jarai, Zsofia, Watya, Stephen, Gaziano, John M., Justice, Amy C., Conti, David V., and Haiman, Christopher A.

Subjects
Article
Abstract

Genome-wide polygenic risk scores (GW-PRS) have been reported to have better predictive ability than PRS based on genome-wide significance thresholds across numerous traits. We compared the predictive ability of several GW-PRS approaches to a recently developed PRS of 269 established prostate cancer risk variants from multi-ancestry GWAS and fine-mapping studies (PRS (269) ). GW-PRS models were trained using a large and diverse prostate cancer GWAS of 107,247 cases and 127,006 controls used to develop the multi-ancestry PRS (269) . Resulting models were independently tested in 1,586 cases and 1,047 controls of African ancestry from the California/Uganda Study and 8,046 cases and 191,825 controls of European ancestry from the UK Biobank and further validated in 13,643 cases and 210,214 controls of European ancestry and 6,353 cases and 53,362 controls of African ancestry from the Million Veteran Program. In the testing data, the best performing GW-PRS approach had AUCs of 0.656 (95% CI=0.635-0.677) in African and 0.844 (95% CI=0.840-0.848) in European ancestry men and corresponding prostate cancer OR of 1.83 (95% CI=1.67-2.00) and 2.19 (95% CI=2.14-2.25), respectively, for each SD unit increase in the GW-PRS. However, compared to the GW-PRS, in African and European ancestry men, the PRS (269) had larger or similar AUCs (AUC=0.679, 95% CI=0.659-0.700 and AUC=0.845, 95% CI=0.841-0.849, respectively) and comparable prostate cancer OR (OR=2.05, 95% CI=1.87-2.26 and OR=2.21, 95% CI=2.16-2.26, respectively). Findings were similar in the validation data. This investigation suggests that current GW-PRS approaches may not improve the ability to predict prostate cancer risk compared to the multi-ancestry PRS (269) constructed with fine-mapping.

Published
2023

181. ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D

Author

Komura, Kazumasa, Yoshikawa, Yuki, Shimamura, Teppei, Chakraborty, Goutam, Gerke, Travis A., Hinohara, Kunihiko, Chadalavada, Kalyani, Jeong, Seong Ho, Armenia, Joshua, Du, Shin-Yi, Mazzu, Ying Z., Taniguchi, Kohei, Ibuki, Naokazu, Meyer, Clifford A., Nanjangud, Gouri J., Inamoto, Teruo, Lee, Gwo-Shu Mary, Mucci, Lorelei A., Azuma, Haruhito, Sweeney, Christopher J., and Kantoff, Philip W.

Subjects
DNA sequencing -- Usage, Antiretroviral agents -- Dosage and administration, Prostate cancer -- Care and treatment -- Risk factors, Health care industry
Abstract

Epigenetic modifications control cancer development and clonal evolution in various cancer types. Here, we show that loss of the male-specific histone demethylase lysine-specific demethylase 5D (KDM5D) encoded on the Y chromosome epigenetically modifies histone methylation marks and alters gene expression, resulting in aggressive prostate cancer. Fluorescent in situ hybridization demonstrated that segmental or total deletion of the Y chromosome in prostate cancer cells is one of the causes of decreased KDM5D mRNA expression. The result of ChIP-sequencing analysis revealed that KDM5D preferably binds to promoter regions with coenrichment of the motifs of crucial transcription factors that regulate the cell cycle. Loss of KDM5D expression with dysregulated H3K4me3 transcriptional marks was associated with acceleration of the cell cycle and mitotic entry, leading to increased DNA-replication stress. Analysis of multiple clinical data sets reproducibly showed that loss of expression of KDM5D confers a poorer prognosis. Notably, we also found stress-induced DNA damage on the serine/threonine protein kinase ATR with loss of KDM5D. In KDM5D-deficient cells, blocking ATR activity with an ATR inhibitor enhanced DNA damage, which led to subsequent apoptosis. These data start to elucidate the biological characteristics resulting from loss of KDM5D and also provide clues for a potential novel therapeutic approach for this subset of aggressive prostate cancer., Introduction Prostate cancer (PC) is the most common cancer among men in the United States and one of the leading causes of cancer death, with approximately 27,000 deaths per year [...]

Published
2018
Full Text
View/download PDF

185. Supplementary Appendix from Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors

Author

Chakraborty, Goutam, primary, Patail, Nabeela Khan, primary, Hirani, Rahim, primary, Nandakumar, Subhiksha, primary, Mazzu, Ying Z., primary, Yoshikawa, Yuki, primary, Atiq, Mohammad, primary, Jehane, Lina E., primary, Stopsack, Konrad H., primary, Lee, Gwo-Shu Mary, primary, Abida, Wassim, primary, Morris, Michael J., primary, Mucci, Lorelei A., primary, Danila, Daniel, primary, and Kantoff, Philip W., primary

Published
2023
Full Text
View/download PDF

186. Supplementary Table 4 from Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer

Author

Dhillon, Preet K., primary, Penney, Kathryn L., primary, Schumacher, Fredrick, primary, Rider, Jennifer R., primary, Sesso, Howard D., primary, Pollak, Michael, primary, Fiorentino, Michelangelo, primary, Finn, Stephen, primary, Loda, Massimo, primary, Rifai, Nader, primary, Mucci, Lorelei A., primary, Giovannucci, Edward, primary, Stampfer, Meir J., primary, and Ma, Jing, primary

Published
2023
Full Text
View/download PDF

187. Supplementary Figure 1 from The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis

Author

Pettersson, Andreas, primary, Graff, Rebecca E., primary, Bauer, Scott R., primary, Pitt, Michael J., primary, Lis, Rosina T., primary, Stack, Edward C., primary, Martin, Neil E., primary, Kunz, Lauren, primary, Penney, Kathryn L., primary, Ligon, Azra H., primary, Suppan, Catherine, primary, Flavin, Richard, primary, Sesso, Howard D., primary, Rider, Jennifer R., primary, Sweeney, Christopher, primary, Stampfer, Meir J., primary, Fiorentino, Michelangelo, primary, Kantoff, Philip W., primary, Sanda, Martin G., primary, Giovannucci, Edward L., primary, Ding, Eric L., primary, Loda, Massimo, primary, and Mucci, Lorelei A., primary

Published
2023
Full Text
View/download PDF

188. Supplementary Data from Evaluation of 8q24 and 17q Risk Loci and Prostate Cancer Mortality

Author

Penney, Kathryn L., primary, Salinas, Claudia A., primary, Pomerantz, Mark, primary, Schumacher, Fredrick R., primary, Beckwith, Christine A., primary, Lee, Gwo-Shu, primary, Oh, William K., primary, Sartor, Oliver, primary, Ostrander, Elaine A., primary, Kurth, Tobias, primary, Ma, Jing, primary, Mucci, Lorelei, primary, Stanford, Janet L., primary, Kantoff, Philip W., primary, Hunter, David J., primary, Stampfer, Meir J., primary, and Freedman, Matthew L., primary

Published
2023
Full Text
View/download PDF

189. Supplementary Figure from The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer

Author

Chakraborty, Goutam, primary, Nandakumar, Subhiksha, primary, Hirani, Rahim, primary, Nguyen, Bastien, primary, Stopsack, Konrad H., primary, Kreitzer, Christoph, primary, Rajanala, Sai Harisha, primary, Ghale, Romina, primary, Mazzu, Ying Z., primary, Pillarsetty, Naga Vara Kishore, primary, Lee, Gwo-Shu Mary, primary, Scher, Howard I., primary, Morris, Michael J., primary, Traina, Tiffany, primary, Razavi, Pedram, primary, Abida, Wassim, primary, Durack, Jeremy C., primary, Solomon, Stephen B., primary, Vander Heiden, Matthew G., primary, Mucci, Lorelei A., primary, Wibmer, Andreas G., primary, Schultz, Nikolaus, primary, and Kantoff, Philip W., primary

Published
2023
Full Text
View/download PDF

190. Supplementary Figure Legend from A Single Nucleotide Polymorphism in Inflammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer

Author

Schoenfeld, Jonathan D., primary, Margalit, Danielle N., primary, Kasperzyk, Julie L., primary, Shui, Irene M., primary, Rider, Jennifer R., primary, Epstein, Mara M., primary, Meisner, Allison, primary, Kenfield, Stacey A., primary, Martin, Neil E., primary, Nguyen, Paul L., primary, Kantoff, Philip W., primary, Giovannucci, Edward L., primary, Stampfer, Meir J., primary, and Mucci, Lorelei A., primary

Published
2023
Full Text
View/download PDF

193. Table S8 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression

Author

Chakraborty, Goutam, primary, Armenia, Joshua, primary, Mazzu, Ying Z., primary, Nandakumar, Subhiksha, primary, Stopsack, Konrad H., primary, Atiq, Mohammad O., primary, Komura, Kazumasa, primary, Jehane, Lina, primary, Hirani, Rahim, primary, Chadalavada, Kalyani, primary, Yoshikawa, Yuki, primary, Khan, Nabeela A., primary, Chen, Yu, primary, Abida, Wassim, primary, Mucci, Lorelei A., primary, Lee, Gwo-Shu Mary, primary, Nanjangud, Gouri J., primary, and Kantoff, Philip W., primary

Published
2023
Full Text
View/download PDF

194. Supplementary Table 3 from The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis

Author

Pettersson, Andreas, primary, Graff, Rebecca E., primary, Bauer, Scott R., primary, Pitt, Michael J., primary, Lis, Rosina T., primary, Stack, Edward C., primary, Martin, Neil E., primary, Kunz, Lauren, primary, Penney, Kathryn L., primary, Ligon, Azra H., primary, Suppan, Catherine, primary, Flavin, Richard, primary, Sesso, Howard D., primary, Rider, Jennifer R., primary, Sweeney, Christopher, primary, Stampfer, Meir J., primary, Fiorentino, Michelangelo, primary, Kantoff, Philip W., primary, Sanda, Martin G., primary, Giovannucci, Edward L., primary, Ding, Eric L., primary, Loda, Massimo, primary, and Mucci, Lorelei A., primary

Published
2023
Full Text
View/download PDF

195. Supplementary Table 3 from Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer

Author

Dhillon, Preet K., primary, Penney, Kathryn L., primary, Schumacher, Fredrick, primary, Rider, Jennifer R., primary, Sesso, Howard D., primary, Pollak, Michael, primary, Fiorentino, Michelangelo, primary, Finn, Stephen, primary, Loda, Massimo, primary, Rifai, Nader, primary, Mucci, Lorelei A., primary, Giovannucci, Edward, primary, Stampfer, Meir J., primary, and Ma, Jing, primary

Published
2023
Full Text
View/download PDF

196. Data from Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer

Author

Lu, Donghao, primary, Sinnott, Jennifer A., primary, Valdimarsdóttir, Unnur, primary, Fang, Fang, primary, Gerke, Travis, primary, Tyekucheva, Svitlana, primary, Fiorentino, Michelangelo, primary, Lambe, Mats, primary, Sesso, Howard D., primary, Sweeney, Christopher J., primary, Wilson, Kathryn M., primary, Giovannucci, Edward L., primary, Loda, Massimo, primary, Mucci, Lorelei A., primary, and Fall, Katja, primary

Published
2023
Full Text
View/download PDF

198. Supplementary Table 1 from Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer

Author

Dhillon, Preet K., primary, Penney, Kathryn L., primary, Schumacher, Fredrick, primary, Rider, Jennifer R., primary, Sesso, Howard D., primary, Pollak, Michael, primary, Fiorentino, Michelangelo, primary, Finn, Stephen, primary, Loda, Massimo, primary, Rifai, Nader, primary, Mucci, Lorelei A., primary, Giovannucci, Edward, primary, Stampfer, Meir J., primary, and Ma, Jing, primary

Published
2023
Full Text
View/download PDF

199. Figure S2 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression

Author

Chakraborty, Goutam, primary, Armenia, Joshua, primary, Mazzu, Ying Z., primary, Nandakumar, Subhiksha, primary, Stopsack, Konrad H., primary, Atiq, Mohammad O., primary, Komura, Kazumasa, primary, Jehane, Lina, primary, Hirani, Rahim, primary, Chadalavada, Kalyani, primary, Yoshikawa, Yuki, primary, Khan, Nabeela A., primary, Chen, Yu, primary, Abida, Wassim, primary, Mucci, Lorelei A., primary, Lee, Gwo-Shu Mary, primary, Nanjangud, Gouri J., primary, and Kantoff, Philip W., primary

Published
2023
Full Text
View/download PDF

200. Supplementary Tables S6 and S7 from Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer

Author

Hurley, Paula J., primary, Sundi, Debasish, primary, Shinder, Brian, primary, Simons, Brian W., primary, Hughes, Robert M., primary, Miller, Rebecca M., primary, Benzon, Benjamin, primary, Faraj, Sheila F., primary, Netto, George J., primary, Vergara, Ismael A., primary, Erho, Nicholas, primary, Davicioni, Elai, primary, Karnes, R. Jeffrey, primary, Yan, Guifang, primary, Ewing, Charles, primary, Isaacs, Sarah D., primary, Berman, David M., primary, Rider, Jennifer R., primary, Jordahl, Kristina M., primary, Mucci, Lorelei A., primary, Huang, Jessie, primary, An, Steven S., primary, Park, Ben H., primary, Isaacs, William B., primary, Marchionni, Luigi, primary, Ross, Ashley E., primary, and Schaeffer, Edward M., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results